Drugs / 140 mg orally daily if BCR/ABL positive and/or Ph+
140 mg orally daily if BCR/ABL positive and/or Ph+
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02043587 | Jan 2014 → Apr 2022 | acute lymphoblastic leukemia | University of California, San Diego | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 140 mg orally daily if BCR/ABL positive and/or Ph+ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02043587 ↗ |